Completed PHASE2 INTERVENTIONAL 3-arm NCT00902369

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Sponsor: Asahi Kasei Pharma Corporation

Interventions AK106-001616 Active comparator Placebo

Updated 6 times since 2017 Last updated: Jul 21, 2016 Started: May 31, 2009 Primary completion: Oct 31, 2009 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00902369, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Asahi Kasei Pharma Corporation, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asahi Kasei Pharma Corporation

Data source: Asahi Kasei Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bucharest, Romania , Budapest, Hungary , Cambridge, United Kingdom , Frankfurt am Main, Germany , Hamburg, Germany , Hlučín, Czechia , Prague, Czechia , Sheffield, United Kingdom , Uherské Hradiště, Czechia and 2 more locations